Recent Updates
Recently added Catalysts
XTNT Positive Sentiment

Xtant Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue Guidance

Wednesday, May 15, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xtant Medical Holdings, Inc. reported a significant revenue growth of 55% for the first quarter of 2024. The company has raised its revenue guidance for the full year to between $116 million and $120 million. This positive trend highlights the company's strong position in the surgical solutions market for spinal disorders.
Price reaction · baseline $0.791 (2024-05-15 close) · hit after-hours · clean, no other XTNT news in the window
day 0 close · peak
-12.5%
day 1
-9%
day 3
-4.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Revenue growth of 55% in Q1 2024.
  • Raised full year 2024 revenue guidance.
  • Strong performance in surgical solutions market.

Full Press Release Details

Expects Revenue for Full Year 2024 of $116 Million to $120 Million BELGRADE, MT, May 15, 2024 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and

Frequently Asked Questions

What was Xtant Medical's revenue growth in Q1 2024?

Xtant Medical reported a revenue growth of 55% in the first quarter of 2024.

What is the new revenue guidance for 2024?

The company raised its full year 2024 revenue guidance to between $116 million and $120 million.

What market does Xtant Medical focus on?

Xtant Medical focuses on surgical solutions for the treatment of spinal disorders.

ShareAdd on Google
Tags: XTNT Viatris Investor Conferences Healthcare Xtant Medical revenue growth spinal disorders 2024 guidance surgical solutions
Last updated: May 15, 2024

Biotech snapshot

Cash runway
$10M liquidity · $2M/mo burn
~4 mo
High dilution risk